PRTX-100-203 Open-Label, Dose Escalation Study in Adult Patients With ITP

Immune Thrombocytopenia Clinical Trial

Official title:

A Phase 1b Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients With Persistent/Chronic Immune Thrombocytopenia

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02566603
• Other study ID #: PRTX-100-203
• Secondary ID: 2014-005626-35
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: November 2015
• Est. completion date: May 17, 2018

Study information

• Verified date: March 2019
• Source: Protalex, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Pre-clinical and clinical evaluations show that PRTX- 100 has biological activity that may lead to improved platelet levels where these are decreased due to immunological pathologies and that PRTX-100 has an acceptable safety profile. In vivo treatment with PRTX-100 has been shown to raise platelet counts in a mouse model of immune thrombocytopenia (ITP). The primary objective of the study is to assess the efficacy of PRTX-100 in terms of platelet response in patients with chronic/persistent ITP.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 15
• Est. completion date: May 17, 2018
• Est. primary completion date: May 17, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Willing and able to provide written informed consent prior to initiation of any study-related procedures

2. Male or female = 18 years of age

3. ITP that has persisted for = 3 months. ITP must be diagnosed in accordance The American Society of Hematology 2011 Evidence-based Practice Guideline for Immune Thrombocytopenia (Neunert et al. 2011) or the International Consensus Report on The Investigation and Management of Primary Immune Thrombocytopenia (Provan et al. 2010), as locally applicable.

4. Received = 1 typical regimen for the treatment of ITP. Splenectomy is considered one regimen.

5. A mean platelet count of < 30,000/µL with no individual platelet count > 55,000/µL. The mean platelet count must be determined based on 2 platelet counts including one obtained within = 7 days of first PRTX-100 dose and the other within = 30 days of the first dose of PRTX-100.

6. If on corticosteroids, a dose of < 1 mg/kg prednisone per day or equivalent that has been stable for = 21 days prior to the first dose of PRTX-100. High-dose pulse steroid therapy is NOT allowed within 14 days prior to the first dose of PRTX-100.

7. If on steroid-sparing adjunctive immunosuppression with cyclosporine, azathioprine, mycophenolate, or 6-mercaptopurine, the dose must have been stable for = 30 days prior to the first dose of PRTX-100 and must be expected to remain stable through study Day 29, unless dose reduction is required due to toxicities. Treatment with other cytotoxic agents (e.g. cyclophosphamide, vincristine) are not allowed within three months prior to the first dose of PRTX- 100.

8. Any prior treatment with rituximab or any other anti-CD20 agent must have been > 6 months prior to the first dose of PRTX-100

9. If female, must not be pregnant (as indicated by screening negative pregnancy test), must not be nursing and must be one of the following:

• Surgically sterile (bilateral tubal ligation, hysterectomy)

• Postmenopausal with last natural menses > 24 months prior

• Premenopausal and using an acceptable form of birth control. Acceptable forms of birth control include: hormonal contraceptives (implantable, oral, patch) used for = 2 months prior to screening or double barrier methods (any combination of two of the following: intrauterine device [IUD], male or female condom with spermicidal gel, diaphragm, sponge, cervical cap). All premenopausal females must have a negative urine or serum pregnancy test at screening and on Day 1 prior to first PRTX-100 treatment.

Exclusion Criteria:

1. Splenectomy = 90 days prior to the first dose of PRTX-100

2. Exposure to TPO-RA within 2 weeks before inclusion

3. Previous treatment with rituximab within <6 months prior to the first dose of PRTX-100

4. Bleeding score = 8 (Khellaf M et al. Haematologica 2005)

5. Unstable coronary artery disease or other medical condition (such as type 1 diabetes) that, in the investigator's opinion, might increase the risk to the patient

6. Evidence of active infection requiring antibiotic therapy = 14 days prior to the first dose of PRTX-100

7. Myelodysplastic syndrome. If clinically significant anemia or pancytopenia exists, documentation of a bone marrow aspirate within 24 months prior to the first dose of PRTX- 100 showing no evidence of myelodysplasia is required.

8. Medical history systemic lupus erythematosus or any cause of secondary ITP

9. History of any treatment for cancer within the past two years other than basal cell or squamous cell carcinoma of the skin that has been treated with curative intent

10. Seropositive for human immunodeficiency virus (HIV)

11. History of acute/chronic hepatitis B or C and/or carriers of hepatitis B or C (positive for hepatitis B surface antigen or positive anti-hepatitis C antibody test)

12. History suggestive of substance abuse

13. Clinically significant abnormalities in screening laboratory tests, including:

• Absolute neutrophil count < 1.0 x109/L

• Hemoglobin < 10 g/dL

• Absolute lymphocyte count < 0.8 x109/L

• Alanine transaminase (ALT) or aspartate transaminase (AST) > 2 x upper limit of normal (ULN)

• Lactate dehydrogenase > 3 x ULN

• Total bilirubin level >1.5 x ULN

• Serum creatinine level > 0.14 mmol/L (1.6 mg/dL) in males or 0.12 mmol/L (1.4 mg/dL) in females

14. Treatment with IVIG = 14 days prior to the first dose of PRTX-100

15. Treatment with an anti-Rh D antigen agent (e.g. WinRho®) = 14 days prior to the first dose of PRTX-100

16. Use of any investigational drug = 30 days or 5 half-lives of the investigational drug (whichever is longer) prior to the first dose of PRTX-100

Related Conditions & MeSH terms

• Immune Thrombocytopenia
• Purpura, Thrombocytopenic, Idiopathic
• Thrombocytopenia

Intervention

Drug:
• PRTX-100
Four weekly infusions of PRTX-100 at a level of 3 micrograms of PRTX-100 per kilogram of patient weight, infused over 30 minutes, followed by four hours of observation after start of infusion.
• PRTX-100
Four weekly infusions of PRTX-100 at a level of 6 micrograms of PRTX-100 per kilogram of patient weight, infused over 30 to 60 minutes, followed by four hours of observation after start of infusion.
• PRTX-100
Four weekly infusions of PRTX-100 at a level of 12 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
• PRTX-100
Four weekly infusions of PRTX-100 at a level of 18 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
• PRTX-100
Four weekly infusions of PRTX-100 at a level of 24 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.

Locations

Country	Name	City	State
France	Côte de Nacre Hospital	Caen
France	Mondor Hospital	Créteil
France	University Hospital	Dijon
France	Claude Huriez Hospital	Lille
France	CH La Timone	Marseille
France	CHU	Nantes
France	Haut-Levêque Hospital	Pessac	Bordeaux
France	CH Lyon Sud	Pierre-Bénite	Lyon
France	Canceropole	Toulouse
United Kingdom	Guy's and St. Thomas Hospital	London	UK
United Kingdom	Hammersmith Hospital	London	OHS
United Kingdom	Royal London Hospital	London
United Kingdom	St. Georges' Hospital	London	UK
United Kingdom	UCLH	London	UK
United Kingdom	Derriford Hospital	Plymouth	UK
United Kingdom	University Hospital Southampton	Southampton	UK

Sponsors (1)

Lead Sponsor	Collaborator
Protalex, Inc.

Countries where clinical trial is conducted

France,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with treatment-related adverse events as assessed by Toxicity Grading Criteria based on RCTC v 2.0 and CTCAE v 4.03	Adverse events from AEs, SAEs, infusion reactions, clinical laboratory tests (hematology, blood chemistry and urinalysis), vital signs, physical findings and ECGs over the course of the study. AE severity will be graded according to Toxicity Grading Criteria derived from published standards.	337 Days
Secondary	Overall platelet response, change from baseline (Day 1)	Defined as a platelet count = 30,000/µL and at least a doubling of baseline platelet count in patients with a baseline platelet count <30,000/µL in the absence of any concomitant rescue therapy.	Days 1, 3, 8, 15, 22, 29, 36, 43, 50, 78, 106, 169, and 337
Secondary	Complete platelet response (number of patients)	The number of patients demonstrating a complete platelet response, defined as a platelet count = 100,000/µL.	Days 3, 8, 15, 22, 29, 36, 43, 50, 78, 106, 169, and 337
Secondary	Time to platelet response (number of days)	The mean number of days from first PRTX-100 dose (Day 1) until platelet response.	Days 3, 8, 15, 22, 29, 36, 43, 50, 78, 106, 169, and 337
Secondary	Durability of platelet response (number of days)	The number of days from first documented platelet response to first platelet count below platelet response criteria.	Days 3, 8, 15, 22, 29, 36, 43, 50, 78, 106, 169, and 337
Secondary	Concomitant ITP medication use (number of subjects)	The number of subjects considered non-responders based on concomitant ITP medication use by cohort and overall. ITP medications include thrombopoietin receptor agonists (TPO-RAs), steroid-sparing adjunctive immunosuppressive treatment (e.g. cyclosporine, azathioprine, mycophenolate), and any ITP rescue medications (e.g. IVIG) received during the study Screening and Treatment Periods.	337 Days